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Case Presentation
We present a 76-year-old Caucasian woman who was admitted to our Acute Neurology Ward. 
She had a previous history of hypertension, hypercholesterolemia, GERD, and non-metastatic HER-
2 positive breast cancer. The breast cancer successfully had been treated radically with left-sided 
mastectomy, axillary evacuation of nodules with no nodular spreading and no cancer recurrence 
since 20 years. The treatment was felt to be curative at the time of diagnosis and no concomitant 
radiation, chemotherapy or anti-HER-2 treatment was offered. Her oncological treatment and 
follow-up terminated one year after diagnosis of the localized breast cancer. The patient’s primary 
care provider had first referred her to an outpatient Clinic for Memory and Cognitive disorders due 
to restless legs syndrome, locomotor and progressive cognitive problems suggestive of dementia. 
Prior to referral, she presented with bradykinesia during 6 months and for one year she had been on 
medication for restless legs syndrome with pramipexol in the primary care sector. Both the patient 
and relatives had noted decreased locomotor speed and difficulty walking. The patient accepted 
giving-up driving a car. She was still responsible for financial matters with a previous job in book-
keeping, her husband, however, complained of new episodes of miscalculations. Due to progression 
in visuospatial dysfunction and visual hallucination within one year of diagnosis of Parkinsonism, 
a diagnosis of Dementia with Lewy Bodies was suspected and the patient instead was admitted 
to an acute Neurology ward prior to her scheduled outpatient Memory Clinic appointment. On 
neurological evaluation she presented with non-tremor dominant parkinsonistic features including 
oligomimia, stooping shuffling gait, movement en-bloc, cork-wheel rigidity of upper limbs and 
positive pull-test. Finger-tapping bilaterally with decrement, left more than right, alternating 
movement with bradykinesia but without dysdiadokinesia, saccades were hypometric. There was 
no evidence of gaze palsy, retrocollis or frontal hyperactivity suggestive of Progressive Supranuclear 
Palsy. No spasticity or alien limb phenomenon was evident suggestive of Corticobasal degeneration. 
A bilateral proximal paresis of the hip was noted, however, deep tendon reflexes were normal. Of 
note, no signs of Babinski were present neither left nor right. Furthermore, the patient appeared 
moderately cognitively impaired with apraxia, visuospatial dysfunction, impaired immediate recall 
and memory. She also revealed signs of executive dysfunction including perseveration, disinhibition 
and poor judgement. Left-sided visual neglect was noted. Complaints had worsened within weeks 
including leg cramps and headache. Acute CT head, followed by MRI headand spine (Figure 1) were 
requested suspecting an expansive process, which was confirmed. MRI spine showed widespread 
leptomeningeal carcinomatosis throughout the spinal canal, with several intramedullary metastases. 
Whole-body FDG-PET CT confirmed widespread involvement as seen on MRI scans (Figure 1) but 
was negative for breast cancer recurrence and showed no additional lung or visceral cancer-spread. 
A neurosurgical procedure was performed with stereotactic biopsy of the solitary brain right 
basal ganglia tumor, suspecting a brain neoplasm, possibly lymphoma due to patient age and 
medullary seeding, less likely an ependymoma with seeding. Neuropathological evaluation of the 
brain biopsy, excluded the tumor process to be due to malignant melanoma, glioma, lung cancer, 
colo-rectal-, bladder cancer or clear cell carcinoma, Surprisingly, the histopathological evaluation 
revealed a metastatic process which could clearly be distinguished from the surrounding brain 
tissue and revealed recurrence of the previous HER-2 positive adenocarcinoma (Figure 2). The 
patient received five sessions of palliative whole brain radiotherapy and was started anti-hormonal 
treatment. Her performance score, however, was already severely impaired at treatment initiation 
and the patient was not considered a candidate for adjuvant chemotherapy or antibody treatment. 
She was released to a hospice, still on anti-hormonal treatment and expired about one month after 
the diagnosis of breast-cancer brain metastasis. 
Abstract
We present a case of a woman with progressive parkinsonistic features, and a previous history of breast 
cancer with no recurrence since 20 years.
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Figure 1: MRI brain reveals a large contrast-enhancing expansive process involving the right basal ganglia and frontal lobe edema, mass-effect and midline shift 
(A, B). MRI spine (C) and whole body FDG-PET CT with intramedullary metastasis (arrows).
Figure 2: A right frontal biopsy was performed showing a disorganized tumoral process with no clear evidence of glandular arrangement (A). Cells revealed 
pleomorphic nuclei and mitotic figures. Stains were negative for melan A, CD45, GFAP, TTF-1, CK-20, p40 and napsin (not shown). The tumor stained positive 
for CK7 (B), estrogen-receptor (C) and HER-2 (D) antibodies consistent with a metastatic process from previous breast cancer.
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Discussion
This case report presents the rare case of a woman with isolated 
CNS involvement from a previous localized primary breast cancer. 
In concordance with the stage at initial breast cancer diagnosis, the 
patient was a disease-free survivor and had had no recurrence or 
metastatic disease during the past 20 years prior to admission. It is 
well known that HER-2 positive breast-cancer frequently metastasizes 
to the brain [1]. Several studies demonstrate a correlation with tumor 
stage and risk of brain metastasis [2]. However rare, it has been shown 
that HER-2 brain metastasis may occur even at 20 years of follow-
up low-grade HER-2 positive breast-cancer [3,4]. In accordance 
with this, our patient had been diagnosed with grade II HER2-
positive breast cancer 20 years prior to diagnosis of breast-cancer 
brain metastasis. Renewed mammography was not requested by the 
oncologist prior to the patient´s death, due to rapid deterioration at 
time of relapse. At time of breast cancer diagnosis the patient solely, 
underwent left-sided mastectomy and axillary evacuation of lymph 
nodes revealing no metastatic spread to any lymph-node station 
(n=11) and no adjuvant treatment was initiated. Isolated widespread 
CNS involvement with no obvious evidence of tumor recurrence 
extracranially 20 years after initial breast cancer diagnosis is unusual. 
One may hypothesize that a HER-2 positive low malignant cancer cell 
clone might have nested in the CNS and escaped immunosurveillance 
being trapped behind a closed blood-brain barrier. Although, rapid 
progression of Parkinsonism with progressive cognitive symptoms 
such as hallucination is highly consistent with a clinical diagnosis of 
dementia with Lewy body, any neurological symptoms in patients 
with previous HER-2 positive breast-cancer irrespective of previous 
tumor grade and disease-free interval should prompt consideration 
of requesting an immediate brain scan in order to exclude CNS 
metastasis. Of note, the patient did not have any complaints of 
headache in the months ahead of admission, a red-flag which would 
otherwise guard most health care providers, and possibly correlated 
to the development of mass effect seen on MRI scans (Figure 1). 
This case highlights the need for awareness of long-term breast-
cancer brain metastasis, even in low-grade HER-2 positive patients. 
The widespread metastatic disease of brain and spinal cord at time of 
diagnosis in our patient was rapidly fatal. Long-term survival (>5 yrs) 
of metastatic HER-2 brain metastasis has been reported, especially 
in patients receiving adjuvant treatment [5]. Although, speculative, a 
scan of both brain and spinal cord at time of prodromal Parkinsonian 
symptoms such as restless legs syndrome or at time of presentation 
of Parkinsonism, might have led to a more favorable outcome in our 
patient.
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